



Annual

GALIEN FORUM

PERSHING SQUARE
FOUNDATIONAtrial
fibrillationLife Science
Venture CapitalInflammatory
skin diseasesNew Wave Innovations
in VaccinesKeynote Drug Pricing and
Trump AdministrationSpinal Muscular
Atrophies

Prions

1

2017

New York City, October 26, 2017

Alexandria Center™ for Life Science
450 East 29th Street, 2nd Floor, between 1st Avenue and the East River, NYCA LEADING
GLOBAL HEALTHCARE &
LIFE SCIENCE EVENT

IN THE PROGRAM:

07:15-07:45 am	Registration and coffee
07:45-08:00 am	Welcome
08:00-09:10 am	<p>Atrial Fibrillation</p> <p><i>Sponsored by:</i></p>  <p>Bengt Samuelsson, MD, PhD, Chair, Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation</p> <p>Carina Blomström-Lundqvist, Professor of Cardiology, Uppsala University, Sweden</p> <p>John Camm, Professor of Clinical Cardiology - St George's, University of London</p> <p>Jörg Kreuzer, Therapeutic Area Head Medicine CV at Boehringer Ingelheim Pharma GmbH & Co. KG</p> <p>Vivek Reddy, Professor Medicine, Cardiology, Mount Sinai Hospital, New York</p> <p>Lars Rydén, Cardiology Unit, Lars Rydén, MD, Dr h.c., HMRCP, FESC, FACC, FAHA, Senior Professor of Cardiology at Karolinska Institute, Stockholm, Sweden</p>
09:10-10:20 am	<p>Addressing Unmet Medical Needs with Early-stage Life Science Venture Capital</p> <p><i>Sponsored by:</i></p>  <p>Joel Marcus, Co-Moderator, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments; Co-Founder, Alexandria Summit</p> <p>Lynne Zydowsky, PhD, Co-Moderator, President & Co-Founder, Alexandria Summit; Chief Science Advisor to the CEO, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments</p> <p>Jean Francois Formela, MD, Partner, Atlas Ventures</p> <p>George Scangos, PhD, CEO & Director, VIR Biotechnology</p> <p>Ryan Watts, PhD, CEO, Denali Therapeutics</p> <p>Krishna Yeshwant, MD, General Partner, GV (Not confirmed)</p>
10:20-10:45 am	Coffee Break
10:45-11:55 am	<p>Inflammatory Skin Diseases and Mechanistic Interconnections to other Inflammation Disorders</p> <p><i>Sponsored by:</i></p>  <p>Mikael Dolsten, MD, PhD, Chair, President, Worldwide Research and Development, Pfizer Inc.</p> <p>Jim Krueger, MD, PhD, Laboratory for Investigative Dermatology, Rockefeller University</p> <p>Dan Littman, NYU, Former President of American Association of Immunology</p> <p>Jonathan Sheldon, PhD, Global Vice President, Healthcare, Health Sciences Global Business Unit, Oracle</p> <p>George Yancopoulos, MD, PhD, Chief Scientific Officer of Regeneron Pharmaceuticals and President, Regeneron Laboratories</p>
11:55 am-01:05 pm	<p>Preparing for the Next Pandemic: Development and Delivery of New Wave Innovations in Vaccines</p> <p>Julie Louise Gerberding, MD, MPH, Chair, Executive Vice-President, Chief Patient Officer and Head of Policy, Communications, and Population Health for Merck & Co., Inc.</p> <p>Mark Feinberg, MD, CEO of IAVI</p> <p>Richard Hatchett, MD, CEO of CEPI</p> <p>Steve Whitehead, PhD, NIH National Institute for Allergies and Infectious Disease [NIAID]</p>
01:05-01:35 pm	Lunch Break
01:35-02:55 pm	<p>Keynote: Drug Pricing and Access in the Trump Administration: Consensus or Confrontation?</p> <p>Introduction: Stephen J. Ubl, President and Chief Executive Officer, PhRMA</p> <p>P. Roy Vagelos, MD, Chair, Chairman of Regeneron Pharmaceuticals and Retired Chairman and Chief Executive Officer of Merck & Co., Inc.</p> <p>Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center</p> <p>Steve Miller, MD, Senior Vice President and Chief Medical Officer, Express Scripts</p> <p>Steve Pearson, MD, Founder and President, Institute for Clinical and Economic Review (ICER)</p> <p>Leonard Schleifer, MD, PhD, Founder, President and CEO, Regeneron Pharmaceuticals</p>
02:55-04:05 pm	<p>Spinal Muscular Atrophy: Charting the Pathway to Clinical Progress</p> <p>Story Landis, PhD, Chair, former Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), and Co-Founder of the NIH BRAIN Initiative</p> <p>C. Frank Bennett, PhD, Senior Vice-President of Research, Ionis Pharmaceuticals</p> <p>Darryl De Vito, MD, Sidney Carter Professor of Neurology and Pediatrics, Columbia University Medical Center</p> <p>Adrian R. Krainer, Ph.D., St. Giles Foundation Professor of Molecular Genetics, Program Chair, Cancer & Molecular Biology, Cold Spring Harbor Laboratory, Watson School of Biological Sciences</p> <p>Alfred Sandrock, MD, PhD, Executive Vice-President and Chief Medical Officer, Biogen</p> <p>Kathie M. Bishop, Ph.D. Chief Scientific Officer, Otonomy</p>
04:05-06:00 pm	<p>Closing Symposium:</p> <p>Treating Neurodegenerative Disease: The Potential of Prion-based Therapies</p> <p>Stanley Prusiner, MD, Chair, Nobel Laureate, Professor of Neurology and Biochemistry at the UCSF</p> <p>Marc Diamond, MD, Distinguished Chair in Basic Brain Injury and Repair and Director, Center for Alzheimer's and Neurodegenerative Disease, the University of Texas, Southwestern Medical Center</p> <p>Eric Kandel, PhD, Nobel Laureate, Professor and Fred Kavli Professor, Department of Neuroscience, Columbia University, New York</p> <p>Roy Parker, PhD, Professor Cech-Leinwand Endowed Chair of Biochemistry at the University of Colorado, Boulder, Colorado</p> <p>Amanda Woerman, PhD, Assistant Professor of Neurology, Institute for Neurodegenerative Diseases, University of California, San Francisco</p>

For more information,
please contact our offices
212 685 1592
forum@galienfoundation.org

REGISTER NOW

Share:

